Evaxion Expands AI-Immunology Platform to Autoimmune Diseases

Generated byAinvest NewsReviewed byThe Newsroom

Monday, Sep 14, 2026 8:14 am ET1min read

EVAX--

Aime Summary

- Evaxion A/S expands AI-Immunology platform to target autoimmune diseases with novel therapies.

- Platform aims to develop treatments with higher efficacy and reduced side effects through unique immunology insights.

- Company will present initial data at 2026 Lisbon summit on November 18, showcasing two AI-driven treatment concepts.

- Tested approaches include tolerogenic vaccines and autoantibody binders to address severe autoimmune conditions.

Evaxion A/S expands its focus to autoimmune diseases, applying its AI-Immunology platform to target underlying pathologies. The platform's unique capabilities could lead to new treatments with higher efficacy and fewer side effects. Initial experimental data will be presented at the Protein & Antibody Engineering Summit in Lisbon on November 18, 2026. The company is testing two novel AI-Immunology-based treatment concepts, a tolerogenic vaccine and an autoantibody binder, with potential to improve treatment options for severely debilitating autoimmune diseases.

Ainvest News

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue